PGY2 Oncology Pharmacy Resident The Johns Hopkins Hospital Baltimore, Maryland, United States
Poster Abstract:
Background: Ambulatory oncology pharmacy practice is an area of increasing importance due to the rapid development of oral anticancer agents. In 2020, 67% of newly approved cancer agents were oral (1). This changing environment highlights the need for institutions to adapt and develop robust oral anticancer programs, involving pharmacists, to assist with medication education, adherence, and adverse effects. The Hematology/Oncology Pharmacist Association (HOPA) recommends that every patient should receive education for their oral anticancer agent separate from the oncologist’s visit and before the start of therapy (2). The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC at JH) has the opportunity to evolve practice to consistently meet the current standards.
Objectives: The primary objective is to design a process that ensures scheduled patient education and follow up visits with ambulatory oncology pharmacists for all new start oral anticancer agents in the hematologic malignancies clinic. This project will also describe the steps needed to bill for ambulatory oncology pharmacy services and develop a system to quantify and assess the impact of ambulatory oncology pharmacy services.
Methods: The current ambulatory oncology oral anticancer management process will be mapped out and a gap analysis will be performed. Additionally, the patient volume will be determined to assess the feasibility of a new proposed process utilizing current resources. All new oral anticancer prescriptions and unique patients will be categorized.
A literature review will be completed to evaluate current practices at other institutions. Additionally, pharmacy organization forums and electronic mailing lists such as HOPA and The American Society of Health-System Pharmacists (ASHP) will be used to review previously submitted content regarding ambulatory oncology practice. The literature and gathered information on other practices will be analyzed to identify successful ambulatory oncology models that have been implemented at other institutions and consider what may be adaptable at SKCCC at JH.
Next, key stakeholders as well as internal and external resources throughout The Johns Hopkins Health System will be identified and queried. Meetings to collaborate with key stakeholders to develop and pilot a new process will be conducted.
Results: Pending
Discussion/
Conclusion: Pending
References (must also be included in final poster): 1. Doshi SD, Lichtenstein MRL, Beauchemin MP, et al. Factors Associated With Patients Not Receiving Oral Anticancer Drugs. JAMA Netw Open. 2022;5(10). 2. Mackler E, Segal EM, Muluneh B, Jeffers K, Carmichael J. 2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard. J Oncol Pract. 2019;15(4).
